Dilated Cardiomyopathy - Pipeline Review, H1 2018

  • ID: 4451683
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • C&C BioPharma LLC
  • Capricor Therapeutics Inc
  • Hemostemix Inc
  • Kasiak Research Pvt Ltd
  • MyoKardia Inc
  • MORE
Dilated Cardiomyopathy - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2018, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular)
  • The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • C&C BioPharma LLC
  • Capricor Therapeutics Inc
  • Hemostemix Inc
  • Kasiak Research Pvt Ltd
  • MyoKardia Inc
  • MORE
Introduction

Dilated Cardiomyopathy - Overview

Dilated Cardiomyopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dilated Cardiomyopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dilated Cardiomyopathy - Companies Involved in Therapeutics Development

Array BioPharma Inc

C&C BioPharma LLC

Capricor Therapeutics Inc

Hemostemix Inc

Kasiak Research Pvt Ltd

MyoKardia Inc

Sanofi

Vericel Corp

Dilated Cardiomyopathy - Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Dilated Cardiomyopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixmyelocel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Refacell-DCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-440181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MEF2 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YS-1402 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dilated Cardiomyopathy - Dormant Projects

Dilated Cardiomyopathy - Product Development Milestones

Featured News & Press Releases

Nov 02, 2017: MyoKardia Provides Update on MYK-491

Oct 05, 2017: Vericel Provides Update on ixmyelocel-T at 2017 Cell & Gene Meeting on the Mesa

Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress

May 10, 2017: Vericel Receives FDA Regenerative Medicine Advanced Therapy Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy

Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet

Mar 28, 2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy

Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy

Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T

Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc, H1

Dilated Cardiomyopathy - Pipeline by C&C BioPharma LLC, H1

Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics Inc, H1

Dilated Cardiomyopathy - Pipeline by Hemostemix Inc, H1

Dilated Cardiomyopathy - Pipeline by Kasiak Research Pvt Ltd, H1

Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H1

Dilated Cardiomyopathy - Pipeline by Sanofi, H1

Dilated Cardiomyopathy - Pipeline by Vericel Corp, H1

Dilated Cardiomyopathy - Dormant Projects, H1

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Array BioPharma Inc
  • C&C BioPharma LLC
  • Capricor Therapeutics Inc
  • Hemostemix Inc
  • Kasiak Research Pvt Ltd
  • MyoKardia Inc
  • Sanofi
  • Vericel Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll